Clinical trials of glycoprotein IIb/IIIa inhibitors

Journal of Interventional Cardiology

Volumn 14, Issue 2, 2001, Pages 129-142

  Talley, J D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; TIROFIBAN;

ARTICLE; DRUG POTENCY; DRUG SAFETY; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; Q WAVE; REVASCULARIZATION; ST SEGMENT; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

EID: 0035004113     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2001.tb00724.x     Document Type: Article

References (38)

1. Pathogenesis of acute ischemic coronary syndromes
2. Medical management of acute coronary syndromes
3. Interventional management of acute coronary syndromes
4. Pharmacology of GP IIb/IIIa inhibitors
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
6. 3 blockade with percutaneous coronary intervention
7. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
8. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
9. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial
10. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
11. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
12. Abciximab (c7E3 Fab): A review of its pharmacology and therapeutic potential in ischemic heart disease
13. Readministration of abciximab: Interim report of the ReoPro readministration registry
14. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms
15. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention
16. 2+ on GP IIb/IIIa interactions with integrilin: Enhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
17. Design and methodology of the PURSUIT trial: Evaluating eptifibatide for acute ischemic coronary syndromes
18. Eptifibatide during immediate percutaneous coronary intervention (PCI) in the acute coronary syndromes (ACS): Findings from the PURSUIT study
19. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
20. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
21. The EPISTENT trial at 6 months: Relative and combined effects of abciximab and stenting on reduction of acute ischemic events and late revascularization
22. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)
23. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions
24. Prognostic implication of creatine kinase elevation following elective coronary artery interventions
25. Six-month anglographic outcome with abciximab and stents: The EPISTENT angiographic substudy
26. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
27. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
28. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
29. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
30. Cardiac troponin T levels for risk stratification in acute myocardial ischemia
31. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies
32. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
33. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
34. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
35. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial
36. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: Preliminary results from the GUSTO-4 pilot (SPEED) dose-ranging trial
37. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction
38. INTRO AMI: Marked enhancement of arterial patency with eptifibatide and lowdose tPA in acute myocardial infarction